Johnson & Johnson makes money in two ways. Its Innovative Medicine segment sells prescription drugs for cancer, immune system diseases, mental health conditions, and other serious illnesses. Its MedTech segment sells devices and tools that doctors use in surgeries, heart procedures, eye care, and joint replacements. Patients and hospitals keep needing these products again and again, which means revenue flows in continuously rather than from one-time sales. The diagram below traces where the money goes.

Five years of financial data show a company generating enormous and consistent cash, even as its shape has changed significantly. Revenue dipped from $93.8 billion in 2022 to $85.2 billion in 2023, largely because Johnson & Johnson separated its consumer brands business into a new company called Kenvue, removing products like Tylenol and Band-Aid from its books. After that separation, the remaining business grew back to $94.2 billion in 2025. That is not just a recovery; it reflects the underlying pharmaceutical and medical device business growing on its own.

Gross margin has held remarkably steady throughout this transformation. It sat at 68.2% in 2022 and was 67.9% in 2025, with only small movements in between. That kind of stability across a major corporate restructuring tells you the core products carry strong pricing power. Free cash flow, which is the money left after the company pays for buildings and equipment, came in at $19.8 billion in 2022, dipped to $18.2 billion in 2023, and was back at $19.7 billion in 2025. The cash generation engine has barely moved.

Net debt tells a different story. It was $19.3 billion in 2022, fell sharply to $7.5 billion in 2023 as Kenvue proceeds came in, then rose again. By 2025 it had climbed to $28.2 billion. The main reason is acquisitions. The company spent roughly $14.5 billion to acquire Intra-Cellular Therapies in April 2025, gaining the psychiatric drug CAPLYTA. It also acquired Shockwave Medical for its cardiovascular devices. Johnson & Johnson is actively spending cash to buy future revenue, which increases debt now in exchange for growth later.

The single clearest financial threat visible in the data is what happened to STELARA, the company's second-largest product. Biosimilar competitors entered the market, and STELARA sales fell from $10.4 billion in 2024 to $6.1 billion in 2025. That is a drop of $4.3 billion in one year from a single product. The Innovative Medicine segment still grew 6% overall in 2025 because DARZALEX, TREMFYA, CARVYKTI, and SPRAVATO expanded fast enough to compensate. But the STELARA collapse illustrates exactly how quickly a major revenue source can disappear when patent protection ends.

The risk picture beyond biosimilars is broad and specific. The U.S. government is actively setting prices for certain Johnson & Johnson drugs under the Inflation Reduction Act. XARELTO, STELARA, and IMBRUVICA have already appeared on the government's selected drug list, with prices taking effect in 2026. ERLEADA joined the list for 2028. The company filed a lawsuit challenging the program's constitutionality and was seeking U.S. Supreme Court review as of December 2025, but the outcome is unresolved. Meanwhile, the company faces thousands of lawsuits related to talc-containing products. In 2025 it reversed approximately $7.0 billion of previously set-aside reserves, suggesting it believes its legal exposure has improved, but the filings warn that final judgments could still exceed what the company has reserved.

Supply chain risk is also documented and specific. Johnson & Johnson runs 63 manufacturing facilities and depends on thousands of suppliers worldwide. A fire, natural disaster, labor shortage, or quality failure at any one facility can halt production and create product shortages. Separately, geopolitical tensions including the Russia-Ukraine war, Middle East conflict, and U.S.-China friction have already raised costs and disrupted logistics. China's volume-based procurement program, where the government forces price cuts on medical devices, directly cut into Surgery and Orthopaedics results in 2025.

The pipeline behind the current drugs is active. TREMFYA is being studied for multiple new conditions including Crohn's disease and ulcerative colitis, which could extend its usefulness well beyond its current psoriasis market. CARVYKTI, the CAR-T cell therapy for blood cancer, grew 95.9% in 2025 as manufacturing capacity expanded. SPRAVATO for treatment-resistant depression grew 57.4%. These are the products Johnson & Johnson is betting will replace the revenue that STELARA has lost and that DARZALEX will eventually lose when its key patents expire in 2029.